Andy

ROCKVILLE, Md., July 30, 2024—The Montgomery County Council voted today to approve the Planning Board Draft of the Great Seneca Plan: Connecting Life and Science with revisions. The plan covers 4,330 acres located in the heart of the I-270 Corridor between the cities of Gaithersburg and Rockville and the town of Washington Grove. The Plan makes recommendations to strengthen the economic competitiveness of the Life Sciences Center, guide future developments, and transform public spaces and amenities in the area to provide valuable links and social spaces. 

“The Great Seneca Science Corridor is one of Montgomery County’s most important strategic areas, as the heart of our globally recognized biohealth industry with world-class research, education, and health care facilities,” said Council President Andrew Friedson who also chairs the Planning, Housing and Parks (PHP) Committee. “This plan builds on that strength by creating a more sustainable and vibrant community with greater connectivity to improve quality of life and economic competitiveness.”

By Dan Brendel – Staff Reporter, Washington Business Journal -Jul 29, 2024 – Montgomery County and Metro have announced a formal partnership and preliminary developer solicitation to pave the way for up to 3.7 million square feet of life science-focused mixed-used development in North Bethesda, the economic development apple of Montgomery County’s eye.

The county and transit authority signed a memorandum of understanding and announced a request for qualifications on Monday, beginning the hunt for a development partner to build a University of Maryland-anchored project, integrated with a new North Bethesda Metro station entrance, on 14 noncontiguous acres of vacant Metro-owned land at the southeast corner of Rockville Pike and Old Georgetown Road.

COLUMBIA, Md., (July 29, 2024) — TEDCO, Maryland’s economic engine for technology companies, announced a recent $100,000 Pre-Seed Builder Fund investment in Azadi Health. TEDCO’s Pre-Seed Builder Fund is housed under TEDCO’s Social Impact Funds which were created to engage and invest in economically underserved founders and communities.

BioHealth Innovation, Inc. (BHI) proudly recognizes the $500,000 investment from TEDCO in Solaxa Inc., a Bethesda-based biopharmaceutical company. Led by Founder & CEO Christian Walker, Solaxa is a clinical-stage biopharmaceutical company developing a portfolio of aminopyridine drugs that both detect and treat ion channel dysfunction. Previous research has shown that aminopyridines can improve nerve signaling and muscle function in patients with Multiple Sclerosis, and Solaxa is presently researching additional benefits in patients with other nerve disorders. Solaxa is organized as a for-profit public benefit corporation, with a mission to advance scientific knowledge and deliver impactful and accessible therapies that improve outcomes for patients worldwide.   

Prior to this investment from TEDCO, Solaxa was recognized as the “Best of Montgomery” finalist at the 7^th Annual BioHealth Capital Region Crab Trap Pitch Competition in September 2023. Even more recently, Solaxa was recognized as “Venture of the Year” by the Maryland Tech Council in May 2024.  

In celebration of the three-year anniversary of JLABS @ Washington, DC (JLABS DC), it’s great timing to highlight recent accomplishments and milestones reached by incubating and regional companies. Additionally, JLABS DC is excited to share new access to specialized lab equipment to support more innovators within the region. 

Since the start of 2024, there has been continued success for incubating companies that reside at JLABS DC. Examples with recent funding announcements include Nanochon, raising $4 million in a Series Seed Prime, Acclinate closing $7 million in a Series A round, and Tiny Cargo securing investment from Virginia Ventures Partners. 

July 25, 2024 / By Laura Powers: Researchers in George Mason University’s Center for Infectious Disease Research (CIDR) and Tulane National Primate Research Center conducted a breakthrough proof-of-concept study, published in Nature’s Gene Therapy, that found a human immunodeficiency virus (HIV)-like virus particle that could cease the need for lifelong medications. Scientists have made great strides in the treatment of HIV over the past few decades, yet those with the virus must still take antiretroviral therapy for life as the disease is difficult to eradicate. 

WASHINGTON, July 25, 2024 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that it has been awarded a fixed-price contract with the United States Army Medical Materiel Development Activity to support commercial validation of new bottle and replacement blister packaging of ARAKODA^® (tafenoquine), the Company’s malaria prevention product.

This follows the implementation of an increased tablet compression batch size in Q1 2024, planned in anticipation of increasing sales volume in 2024. Recently, 60 Degrees Pharmaceuticals announced that Q1 2024 ARAKODA net sales revenues increased 515% year-over-year to $105.7 thousand.

Ready to take your business to the global stage? Join the Maryland Global Consulting Program through the Robert H. Smith School of Business Center for Global Business and tap into the vibrant export ecosystem right here in Maryland. Gain invaluable insights and resources to expand your company’s global footprint and tackle international business challenges head-on.

Benefits of the Program

1. Customized Consulting Support: Work closely with a dedicated team of business students to develop strategies for global market expansion or address specific international business challenges tailored to your company’s needs. Student teams dedicate a minimum of 10 hours per week per semester to a single consulting project.